Healthcare


 Little Green Pharma Ltd (ASX:LGP) Recovery and Strategic Valuation in the Pharmaceuticals Sector

Little Green Pharma Ltd (ASX:LGP) Recovery and Strategic Valuation in the Pharmaceuticals Sector

February 18, 2025 01:33 PM AEDT| By Team Kalkine Media

Little Green Pharma Ltd (ASX:LGP) Recovery and Strategic Valuation in the Pharmaceuticals Sector

 HMC Capital Considers Healthscope Acquisition with Focus on Workforce Stability

HMC Capital Considers Healthscope Acquisition with Focus on Workforce Stability

February 18, 2025 12:04 PM AEDT| By Team Kalkine Media

Highlights:,HMC Capital explores a potential acquisition of Healthscope, aiming to,maintain,operational stability.,The company,seeks,to minimise facility closures and job reductions as part of the deal.,HealthCo,Healthcare & Wellness REIT,discloses,d...

 Health Check: Brokers Reduce Cochlear Valuations as Customers Delay Product Upgrades

Health Check: Brokers Reduce Cochlear Valuations as Customers Delay Product Upgrades

February 18, 2025 11:00 AM AEDT| By Team Kalkine Media

Biotech Industry Update: Key Developments and Trials

 Health Check: It's Time to Showcase Our Three Local Heroes

Health Check: It's Time to Showcase Our Three Local Heroes

February 18, 2025 11:00 AM AEDT| By Team Kalkine Media

Highlights:,Nanosonics prepares to introduce Coris, a new anti-infection device designed for hospital instrument cleaning.,Cogstate experiences revenue growth, driven by advancements in Alzheimer's disease clinical trials.,Sonic Healthcare reports pr...

 Recce Pharmaceuticals Advances in Fight Against Skin Infections with Promising Phase II Trial Results

Recce Pharmaceuticals Advances in Fight Against Skin Infections with Promising Phase II Trial Results

February 17, 2025 10:18 PM AEDT| By Team Kalkine Media

Highlights:,Positive results from Phase II trial of Recce 327 topical gel,No serious adverse events reported, meeting all safety and efficacy endpoints,Phase III trial for diabetic foot infections approved in Indonesia,Recce Pharmaceuticals (ASX:RCE)...

 ASX Closes Lower as (ASX:AD8) Surges 26% and (ASX:BEN) Faces Sharp Decline

ASX Closes Lower as (ASX:AD8) Surges 26% and (ASX:BEN) Faces Sharp Decline

February 17, 2025 06:11 PM AEDT| By Team Kalkine Media

Highlights,(ASX:AD8) jumps 26% after strong half-year results,(,ASX:BEN,) slides 15% on weaker margins and earnings shortfall,Seven sectors end in the green, with Utilities leading gains,The Australian stock market wrapped up the trading session with...

 Sonic Healthcare (ASX:SHL): A Closer Look at Stock Performance and Long-Term Outlook

Sonic Healthcare (ASX:SHL): A Closer Look at Stock Performance and Long-Term Outlook

February 17, 2025 04:17 PM AEDT| By Team Kalkine Media

Highlights,Sonic Healthcare (SHL) sees a 10% rise in,quarterly,share price.,Shareholder,return over the past three years shows a 23% decline.,Dividends contribute to a less negative total shareholder return (TSR) of -15%.,Sonic Healthcare (ASX:SHL),...

 Recce Pharmaceuticals Shows Promising Results for Topical Gel in Treating Skin Infections, Sets Stage for Phase 3 Study

Recce Pharmaceuticals Shows Promising Results for Topical Gel in Treating Skin Infections, Sets Stage for Phase 3 Study

February 17, 2025 03:20 PM AEDT| By Team Kalkine Media

Highlights,Recce Pharmaceuticals’ Phase II clinical trial of its topical gel, RECCE 327 (R327G), achieved a 93% primary efficacy endpoint in treating Acute Bacterial Skin and Skin Structure Infections, including Diabetic Foot Infections.,The gel demo...

 Recce Pharmaceuticals (ASX:RCE) Advances R327G to Phase III After Positive Phase II Trial Results

Recce Pharmaceuticals (ASX:RCE) Advances R327G to Phase III After Positive Phase II Trial Results

February 17, 2025 01:12 PM AEDT| By Team Kalkine Media

Highlights:,93% Efficacy Rate:,Recce Pharmaceuticals (ASX:RCE) reported that R327G achieved a 93% primary efficacy endpoint in its Phase II trial for bacterial skin infections.,Phase III Progress:,The company is moving forward with Phase III registra...

 Althea Group’s Expansion into the North American THC Beverage Market

Althea Group’s Expansion into the North American THC Beverage Market

February 17, 2025 12:30 PM AEDT| By Team Kalkine Media

Cannabis in a Can: Nanocap Althea Secures $4M to Boost THC Beverage Expansion in the US and Canada

 Recce Pharmaceuticals (ASX:RCE) Advances ABSSSI Treatment with Positive Phase II Trial Results

Recce Pharmaceuticals (ASX:RCE) Advances ABSSSI Treatment with Positive Phase II Trial Results

February 17, 2025 11:30 AM AEDT| By Team Kalkine Media

Breakthrough in Infection Treatment: Recce Pharmaceuticals (ASX:RCE) Reports Strong Clinical Results

 Health Check: After treating its final patient, Opthea anticipates the crucial outcomes of its make-or-break trial.

Health Check: After treating its final patient, Opthea anticipates the crucial outcomes of its make-or-break trial.

February 17, 2025 11:00 AM AEDT| By Team Kalkine Media

Biotech Developments and Market Movements in Focus

 Imugene is well-funded and on the brink of revolutionizing cancer immunotherapy.

Imugene is well-funded and on the brink of revolutionizing cancer immunotherapy.

February 17, 2025 11:00 AM AEDT| By Team Kalkine Media

Highlights:,Imugene is advancing three immunotherapy programs focused on CAR-T therapies and oncolytic viruses.,The company secured new funding through convertible notes, supporting its ongoing clinical trials.,Development of allogeneic CAR-T therapi...

 Will ASX:ARX Reinvent Its Course in a Rapidly Expanding Sector?

Will ASX:ARX Reinvent Its Course in a Rapidly Expanding Sector?

February 16, 2025 11:30 AM AEDT| By Team Kalkine Media

Highlights,ASX:ARX experienced a sharp decline in share price, erasing earlier gains.,The company’s price-to-sales ratio remains much lower compared to many peers in biotechnology.,Recent revenue performance shows steady growth, though it lags behind...

 CSL's Earnings for the First Half of 2025: EPS Falls Short of Expectations

CSL's Earnings for the First Half of 2025: EPS Falls Short of Expectations

February 16, 2025 11:30 AM AEDT| By Team Kalkine Media

Highlights:,CSL Limited (ASX:CSL) reported an increase in revenue in its latest financial results.,Earnings per share came in below expectations despite stable profit margins.,The company's stock declined over the past week amid broader market moveme...

 Can Imagion Biosystems Transform HER2 Imaging for Cancer Diagnostics?

Can Imagion Biosystems Transform HER2 Imaging for Cancer Diagnostics?

February 16, 2025 11:00 AM AEDT| By Team Kalkine Media

Highlights,• MagSense HER2 imaging agent manufacturing commences for advanced clinical trials.,• Innovative imaging technology aims to enhance cancer diagnostics in the HER2+ breast cancer sector.,• Strategic steps underway to file an Investigational...

 What Key Developments Define ASX:PME in Healthcare Imaging?

What Key Developments Define ASX:PME in Healthcare Imaging?

February 14, 2025 03:34 PM AEDT| By Team Kalkine Media

Highlights,Earnings per share growth has been robust.,Company leaders own a considerable portion of stock.,Governance practices and CEO compensation remain conservative.,The healthcare technology sector continues to evolve with advancements in diagno...

 Avita Medical (ASX:AVH) Surges Over 11% on Strong Growth Outlook

Avita Medical (ASX:AVH) Surges Over 11% on Strong Growth Outlook

February 14, 2025 02:21 PM AEDT| By Team Kalkine Media

Highlights,Avita Medical (AVH) shares,jump,over 11% following,revenue,guidance announcement.,Company,projects a 55-65% growth in,full-year,2024 commercial revenue.,Net loss widens due to increased operating expenses.,Avita Medical (ASX:AVH) saw a sha...

 Healius Surges Amid Fresh Merger Talks with Australian Clinical Labs

Healius Surges Amid Fresh Merger Talks with Australian Clinical Labs

February 14, 2025 01:47 PM AEDT| By Team Kalkine Media

Highlights,Healius,(,ASX:HLS,),emerges,as the top performer on the ASX 200 after reports of renewed merger discussions.,Australian Clinical Labs (ASX:ACL) also sees a slight uptick in share value.,Potential $2 billion deal gains attention following p...

 Pro Medicus Gains Momentum as Analysts Raise Price Target

Pro Medicus Gains Momentum as Analysts Raise Price Target

February 14, 2025 01:45 PM AEDT| By Team Kalkine Media

Highlights,Pro Medicus (PME) receives an upgraded outlook with a higher price target.,Shares recover after a dip following,first,-half earnings results.,Analyst boosts the target price by 18%, reflecting strong long-term prospects.,Pro Medicus (ASX:P...

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles






Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.